To investigate the antiviral activity of TPD-based compounds against JEV infection in SH-SY5Y cells, we selected five clinically advanced compounds: CC-90009; CC-92480, a phase III anti-myeloma CELMoD; NVP-DKY709, a phase I anti-tumour CELMoD targeting Ikaros family zinc finger protein 2; ARV-110, a phase II androgen receptor targeting PROTAC; and ARV-471, a phase II oestrogen receptor PROTAC for breast cancer. Here, IKZF2 is linked to neoplasm.